Analysis of the Curative Effect of Surgical Treatment of Early Small Cell Lung Cancer and Study of Serum Tumor Markers

  • Shuanlin Miao
Keywords: Small Cell Lung Cancer, Serum Tumor Markers, Pathological Confirmation, Diagnosis and Treatment


Lung cancer is one of the common malignant tumors, and its morbidity and mortality have been at a high level
in China. Lung cancer treatment methods include surgical treatment, radiotherapy, chemotherapy, biological
treatment, and traditional Chinese medicine treatment, among which surgical treatment plays a leading role.
Small cell lung cancer (SCLC) is a relatively special type of lung cancer pathology. It is a primary malignant
tumor with a high incidence in domestic and foreign countries today, accounting for 15-20% of all lung cancers
in the population. Based on the above background, the purpose of this article is to analyze the efficacy of
surgical treatment of early small cell lung cancer and study the serum tumor markers. In this article, all patients
who were newly diagnosed in a provincial tumor hospital from January 2016 to October 2019 were confirmed
by pathology. The pathological staging was based on postoperative or tissue biopsy pathology, head and chest
enhanced CT, whole body bone scan, and whole body PET-CT. Imaging performance. Then the serum tumor
markers NSE, CYFRA21-1, and CEA in patients with early and late SCLC, early NSCLC, and benign lung
lesions were measured by immunoradiological analysis methods, and retrospective investigation and analysis
were performed. The results showed that the positive rate and concentration of NSE in early SCLC patients
were significantly higher than those in early NSCLC and those with benign lung lesions, and the differences
were statistically significant (P <0.01); the detection rate of early SCLC by NSE was significantly better than
that of CYFRA 21-1. There were statistically significant differences between CEA and CEA (P <0.01); the
detection rates of early squamous cell carcinoma and adenocarcinoma detected by CYFRA21-1 and CEA,
respectively, were significantly higher than those of early SCLC patients, the difference was statistically
significant (P <0.05) The positive rate and concentration of NSE in early small cell lung cancer were lower than
those in advanced small cell lung cancer, and the differences were statistically significant (P <0.05).